Proteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis Patients
An AVF, which is a surgically created connection between an artery and a vein, is the preferred form of vascular access, enabling a patient with chronic kidney disease (CKD) to undergo life-sustaining hemodialysis. AVFs are susceptible to failure, which occurs when an AVF has insufficient blood flow for hemodialysis, most often due to a blockage in the blood vessels of the AVF. AVF failure can result in additional surgical or other corrective procedures, such as balloon angioplasty, and reduced AVF survival.
The poster describes the results of a survey of 60 hemodialysis patients who had previously experienced a failure of their AVF. The survey found that 36% of the patients experienced a missed dialysis session due to AVF failure with a resulting extended interdialytic gap period of at least 2 days and 18% of patients experienced an extended interdialytic gap of at least 3 days. The interdialytic gap is the number of days between hemodialysis treatment sessions. In previous research (Foley, NEJM, 2011), 2 day interdialytic gap periods have been associated with increased rates of morbidity and mortality.
The poster, number 305, "Consequences for Dialysis Patients Suffering Vascular Access Failure", will be available for viewing in the Exhibit Hall at the
About Chronic Kidney Disease, Hemodialysis and Vascular Access
In the most severe stage of chronic kidney disease (CKD), also known as kidney failure, the kidneys can no longer function to sustain life. The majority of patients with kidney failure require hemodialysis and need a high-flow vascular access to repeatedly connect the patient's bloodstream to a hemodialysis machine for this life-saving, chronic treatment. Three times per week for three to four hours each session, blood is pumped from the body and passed through a dialysis machine that removes waste and excess water normally excreted by the kidneys. The preferred form of vascular access, used by two-thirds of hemodialysis patients in
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, "forward-looking statements." In some cases these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential," or, in each case, their negatives or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements, including when the Company expects to report top-line data from the PATENCY-1 Phase 3 clinical study, the number of patients to be enrolled in and the timing of completion of enrollment in the PATENCY-2 Phase 3 clinical study of vonapanitase, the potential surgical and endovascular applications for vonapanitase, the potential treatment of renal and vascular diseases with vonapanitase, the effect of vonapanitase in patients with CKD, whether vonapanitase improves AVF patency and those relating to future events or our future financial performance or condition, involve substantial known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors, including whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements for the period anticipated; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether vonapanitase will advance through the clinical trial process on the anticipated timeline and warrant submission for regulatory approval; whether such a submission would receive approval from the